[177Lu]Lu-EVS459

N/A

Report date: 2025/11/28 15:16:46

Base Information

Drug Name[177Lu]Lu-EVS459

Drug Alias Name[177Lu]Lu-EVS459EVS-459GIZ943GIZ-943

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionRadionuclide imaging enhancersFolate receptor alpha binders

TargetsFolate receptor alpha

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIsrael

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNovartis Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsLung NeoplasmsOvarian Neoplasms

Other Information

ATC CodeN/A